1-chloro-1,3,3-triphenylpropane | 70550-48-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-chloro-1,3,3-triphenylpropane
• 英文别名: 1-Chlor-1,3,3-triphenylpropan；(1-Chloro-3,3-diphenylpropyl)benzene
• CAS: 70550-48-0
• 化学式: C₂₁H₁₉Cl
• 分子量: 306.835
• InChiKey: DKPVADYIAYWCGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  1,3,3-triphenylpropan-1-ol 在 氯化亚砜 作用下， 生成 1-chloro-1,3,3-triphenylpropane
  参考文献：
  名称：

  Electrophilic additions to acetylenes. 7. Relative reactivity of double and triple bonds toward carbenium ions

  摘要：

  DOI：

  10.1021/jo01331a013

文献信息

• Relative reactivities of alkenes toward the diphenylmethyl cation
  作者：Herbert Mayr、Rudolf Pock

  DOI：10.1016/s0040-4039(00)81869-9

  日期：——

  The relative reactivities of alkyl and phenyl substituted alkenes toward diphenylmethyl chloride/ZnCl2/Et2O in dichloromethane at −78°C have been determined by competition experiments. The transition state structure is discussed.

  通过竞争实验确定了烷基和苯基取代的烯烃在二氯甲烷中于-78℃下对二苯基甲基氯/ ZnCl 2 / Et 2 O的相对反应性。讨论了过渡状态结构。
• NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE
  申请人：Suzhou Ribo Life Science Co., Ltd.

  公开号：EP3719125A1

  公开（公告）日：2020-10-07

  Provided are a siRNA for inhibiting the expression of hepatitis B virus gene, and a pharmaceutical composition and conjugate containing the siRNA. Each nucleotide in the siRNA is independently a modified nucleotide. The siRNA comprises a sense strand and an antisense strand. The sense strand of the siRNA comprises a nucleotide sequence 1 having the same length and no more than three nucleotides different from the nucleotide sequence shown in SEQ ID NO: 155, and the antisense strand of the siRNA comprises a nucleotide sequence 2 having the same length and no more than three nucleotides different from the nucleotide sequence shown in SEQ ID NO: 156.

  本文提供了一种用于抑制乙型肝炎病毒基因表达的 siRNA，以及含有该 siRNA 的药物组合物和共轭物。 siRNA 中的每个核苷酸都是独立的修饰核苷酸。 siRNA 包括有义链和反义链。 siRNA 的有义链包括与 SEQ ID NO: 155 所示核苷酸序列具有相同长度且相差不超过三个核苷酸的核苷酸序列 1，而 siRNA 的无义链包括与 SEQ ID NO: 156 所示核苷酸序列具有相同长度且相差不超过三个核苷酸的核苷酸序列 2。
• NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE
  申请人：Suzhou Ribo Life Science Co., Ltd.

  公开号：EP3719127A1

  公开（公告）日：2020-10-07

  The present disclosure provides a siRNA for inhibiting the expression of apolipoprotein C3 (ApoC3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.

  本发明公开了一种用于抑制载脂蛋白C3（ApoC3）基因表达的siRNA，以及包含该siRNA的药物组合物和共轭物；其中，该siRNA中的每个核苷酸都是独立的修饰核苷酸，该siRNA包括有义链和反义链；该有义链包括核苷酸序列A，该核苷酸序列A与SEQ ID NO：1 所代表的核苷酸序列具有相同的长度，但核苷酸差异不超过 3 个；反义链包括核苷酸序列 B，核苷酸序列 B 与 SEQ ID NO:2 所代表的核苷酸序列具有相同的长度，但核苷酸差异不超过 3 个。
• NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD AND USE
  申请人：Suzhou Ribo Life Science Co., Ltd.

  公开号：EP3718572A1

  公开（公告）日：2020-10-07

  Provided are an siRNA for inhibiting expression of a Hepatitis B virus gene, and a pharmaceutical composition and conjugate containing the siRNA. Each nucleotide in the siRNA is an independently modified or unmodified nucleotide; the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A; the length of the nucleotide sequence A is the same as that of a nucleotide sequence as shown in SEQ ID NO: 1, and the number of the nucleotide differences is not more than three; the antisense strand comprises a nucleotide sequence B; and the length of the nucleotide sequence B is the same as that of a nucleotide sequence as shown in SEQ ID NO: 2, and number of nucleotide differences is not more than three.

  本发明提供了一种用于抑制乙型肝炎病毒基因表达的 siRNA，以及含有该 siRNA 的药物组合物和共轭物。siRNA 中的每个核苷酸都是独立修饰或未修饰的核苷酸；siRNA 包括有义链和反义链；有义链包括核苷酸序列 A；核苷酸序列 A 的长度与 SEQ ID NO：1 所示的核苷酸序列相同，且核苷酸差异数目不超过三个；反义链包括核苷酸序列 B；核苷酸序列 B 的长度与 SEQ ID NO: 2 所示的核苷酸序列相同，且核苷酸差异数目不超过三个。
• NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Suzhou Ribo Life Science Co., Ltd.

  公开号：EP3719126A1

  公开（公告）日：2020-10-07

  Provided are a siRNA for inhibiting the expression of an angiopoietin-like protein 3 (ANGPTL3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.

  提供了一种用于抑制血管生成素样蛋白3(ANGPTL3)基因表达的siRNA，以及包含该siRNA的药物组合物和共轭物；其中，siRNA中的每个核苷酸独立地为修饰或未修饰的核苷酸，且siRNA包括有义链和反义链；有义链包括核苷酸序列A，该核苷酸序列A与SEQ ID NO.1所代表的核苷酸序列具有相同的长度，且核苷酸差异不超过3个；反义链包括核苷酸序列B，该核苷酸序列B与SEQ ID NO:1所代表的核苷酸序列具有相同的长度，且核苷酸差异不超过3个；反义链包括核苷酸序列C，该核苷酸序列C与SEQ ID NO:1所代表的核苷酸序列具有相同的长度，且核苷酸差异不超过3个：1 所代表的核苷酸序列具有相同的长度，但核苷酸差异不超过 3 个；反义链包括核苷酸序列 B，核苷酸序列 B 与 SEQ ID NO:2 所代表的核苷酸序列具有相同的长度，但核苷酸差异不超过 3 个。